Search

The article discusses the potential for targeting systemic inflammation in patients with heart failure through leucocyte immunomodulation. It highlights the high incidence of cardiovascular mortality and hospitalizations for heart failure despite current therapies. The role of inflammation in heart failure is explored, with a focus on the involvement of proinflammatory cytokines and biomarkers. The article introduces a novel approach using a selective cytopheretic device (SCD) to target activated neutrophils and monocytes, which has shown promise in reducing systemic inflammation and improving outcomes in other acute conditions. A case report is presented to demonstrate the potential effectiveness of the SCD in bridging patients to left ventricular assist device (LVAD) implantation. The article concludes by suggesting that further studies are needed to evaluate the use of the SCD and its potential to reduce cardiovascular mortality and hospitalizations in heart failure patients. [Extracted from the article]